Collectively, we provide a pathogenic mechanism linking RARRES2 and lipid metabolic reprogramming in the development of BrM in breast cancer, with the anticipation that the RARRES2-dependent metabolic functions may serve as biomarkers or therapeutic targets for BCBrM in TNBC. The gene discussed is RARRES2; the disease is breast cancer.